Endometrial atypical hyperplasia is clinically recognized as a direct precursor to type I endometrial cancer, a malignancy strongly associated with metabolic disturbances such as obesity and insulin resistance. The investigators meticulously quantified serum irisin levels in these patients and compared them with a matched control group free of endometrial pathology. Notably, the authors emphasize the need for larger-scale studies to validate their findings and to establish the clinical utility of measuring irisin levels. Subject of Research: Irisin hormone levels in patients with endometrial atypical hyperplasia and endometrial carcinomaArticle Title: Exploring irisin levels in patients with endometrial atypical hyperplasia and carcinoma: a comparative analysisArticle References:Bildacı, T.B., Ata, C., Atlıhan, U. et al. Exploring irisin levels in patients with endometrial atypical hyperplasia and carcinoma: a comparative analysis.